Nicolás Mendoza

Prof. Dr. Nicolás Mendoza

Obstetrics and Gynecology, University of Granada, Granada, Andalusia, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Maturitas
Verified
Journal Article
Closed access
Nicolás MendozaNicolás Mendoza
Nicolás Mendoza
CTCarlos De Teresa
Carlos De Teresa
ACAntonio Cano
Antonio Cano
DGDÉBORA GODOY-IZQUIERDO
DÉBORA GODOY-IZQUIERDO
Fidel Hita-ContrerasFidel Hita-Contreras
Fidel Hita-Contreras
Rafael Sánchez-BorregoRafael Sánchez-Borrego
Rafael Sánchez-Borrego

1 February 2014 in Maturitas
Verified
Journal Article
Closed access
MVMERCEDES VÉLEZ
MERCEDES VÉLEZ
DGDÉBORA GODOY-IZQUIERDO
DÉBORA GODOY-IZQUIERDO
AGAna Padial García
Ana Padial García
RMRaquel Lara Moreno
Raquel Lara Moreno
Nicolás MendozaNicolás Mendoza
Nicolás Mendoza
JGJuan F. Godoy García
Juan F. Godoy García

20 July 2012 in Gynecological Endocrinology
Verified
Journal Article
Closed access
PDF file
Nicolás MendozaNicolás Mendoza
Nicolás Mendoza
MMMiguel Angel Motos
Miguel Angel Motos
Androgen insensitivity syndrome (AIS) is a disorder caused by a mutation of the gene encoding the androgen receptor (AR; Xq11–q12). The prevalence of AIS has been estimated to be one case in every 20,000 to 64,000 newborn males for the complete syndrome (CAIS), and the prevalence is unknown for the partial syndrome (PAIS). The symptoms range from phenotypically normal males with impaired spermatogenesis to phenotypically normal women with primary amenorrhea. Various forms of ambiguous genitalia have been observed at birth. The diagnosis is confirmed by determining the exact mutation in the AR gene. PAIS individuals require precise diagnosis as early as possible so that the sex can be assigned, treatment can be recommended, and they can receive proper genetic counseling. After birth, differential diagnosis should be performed using other forms of abnormal sexual differentiation of primary amenorrhea. The treatment of AIS is based on reinforcement sexual identity, gonadectomy planning, and hormone replacement therapy. The prognosis for CAIS is good if the testicular tissue is removed at the appropriate time. For PAIS, the prognosis depends on the ambiguity of the genitalia and physical and psychosocial adjustment to the assigned sex.

1 November 2017 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
Nicolás MendozaNicolás Mendoza
Nicolás Mendoza
LPLaura Pérez
Laura Pérez
TSTommaso Simoncini
Tommaso Simoncini
Alessandro GenazzaniAlessandro Genazzani
Alessandro Genazzani

30 August 2022 in Maturitas
Verified
Journal Article
Closed access
Nicolás MendozaNicolás Mendoza
Nicolás Mendoza
IRIsabel Ramírez
Isabel Ramírez
EVEsther de la Viuda
Esther de la Viuda
PCPluvio Coronado
Pluvio Coronado
LBLaura Baquedano
Laura Baquedano
JCJoaquín Calaf
Joaquín Calaf

24 August 2023 in Maturitas
Verified
Journal Article
Open access
AMAitana Monllor-Tormos
Aitana Monllor-Tormos
AGAlicia García-Vigara
Alicia García-Vigara
OMOrly Morgan
Orly Morgan
Miguel Angel García-PérezMiguel Angel García-Pérez
Miguel Angel García-Pérez
Nicolás MendozaNicolás Mendoza
Nicolás Mendoza
ACAntonio Cano
Antonio Cano
Cancer is one of the main noncommunicable diseases in terms of health impact. Factors such as a progressively aging population point to future increases in the incidence of cancer on a global level. The elevated number of affected individuals, together with continuous improvements in cancer prevention and therapy, is creating a growing population of cancer survivors, with often inadequately met needs. Lifestyle is a key modulator of cancer risk and of associated morbidity and mortality, and is included in all approaches to the long-term management of cancer. Diet is a principal component of lifestyle, and most of the available evidence is centered on the Mediterranean diet. Our objective was to provide a narrative review of the evidence on the effect of the Mediterranean diet on cancer risk and health threats related to cancer survivorship. For this purpose, we searched the PubMed database for articles published between January 1, 2000, and June 12, 2023. Current data show that the Mediterranean diet is inversely associated with risk, or is risk neutral, for most types of cancer. Tumors of the digestive system have received preferential interest, but studies have also been published on tumors in other organs. The evidence, however, is meager due to the observational nature of most studies, although it is reassuring that benefit is reproduced in studies performed in different populations and environments. Evidence related to cancer survivors is limited by the paucity of studies, yet several findings regarding survival, recurrence, and short- and long-term morbidity suggest a potential role for the Mediterranean diet that warrants further research.